pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently
available for clinical use and other aspects related to their management. Methods: We …

Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct
activated factor X inhibitors) are increasingly being used in clinical practice. Compared with …

Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for
decades. However, with the US Food and Drug Administration approval of new oral …

Oral anticoagulation has been limited to vitamin K antagonists (VKAs) for over 60 years.
VKAs are effective and recommended for the prevention of venous and arterial …

While parenteral anticoagulants such as unfractionated and low molecular weight heparins
and the oral vitamin K antagonists are effective for the prevention and treatment of …

Although their first application in clinical practice occurred in the 1940s, vitamin K
antagonists remain the only form of oral anticoagulant medication approved for long-term …

Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

Until recently, warfarin had been one of the only treatment options for long-term
anticoagulation of patients with atrial fibrillation, venous thromboembolism, or other medical …

What is known and objective Anticoagulation is important in the management of
cardiovascular disorders; however, traditional anticoagulants such as heparins and vitamin …